Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

NCT ID: NCT05373485

Last Updated: 2024-12-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-17
• Study Completion Date: 2022-08-08

Brief Summary

To evaluate the safety and immunogenicity of the COVID-19 mRNA vaccine in people aged 18 years and older, 80 participants will be enrolled and divided into two groups: low- and high-dose groups. Each dose group will be divided into 2 age groups (20 people each):18 to 59 years old and ≥ 60 years old. Subjects will be randomized into vaccine group or placebo group in a ratio of 3:1. Subjects will receive 2 doses of either vaccine or placebo on Day 0 and Day 21, in which the low-dose group will received 0.3 ml of the study vaccine or placebo, and the high dose group will receive 0.5 ml of the study vaccine or placebo.

Conditions

COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Vaccine Group, low dose, 18-59 year-old

2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21

Group Type: EXPERIMENTAL

COVID-19 mRNA vaccine

Intervention Type: BIOLOGICAL

2 doses of vaccine on Day 0 and Day 21

Vaccine Group, low dose, 60 year-old and above

2 doses of COVID-19 mRNA vaccine (30µg, 0.3 ml) on Day 0 and Day 21

Group Type: EXPERIMENTAL

COVID-19 mRNA vaccine

Intervention Type: BIOLOGICAL

2 doses of vaccine on Day 0 and Day 21

Vaccine Group, high dose, 18-59 year-old

2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21

Group Type: EXPERIMENTAL

COVID-19 mRNA vaccine

Intervention Type: BIOLOGICAL

2 doses of vaccine on Day 0 and Day 21

Vaccine Group, high dose, 60 year-old and above

2 doses of COVID-19 mRNA vaccine (50µg, 0.5 ml) on Day 0 and Day 21

Group Type: EXPERIMENTAL

COVID-19 mRNA vaccine

Intervention Type: BIOLOGICAL

2 doses of vaccine on Day 0 and Day 21

Placebo Group, low dose, 18-59 year-old

2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

2 doses of placebo on Day 0 and Day 21

Placebo Group, low dose, 60 year-old and above

2 doses of placebo (0µg, 0.3 ml) on Day 0 and Day 21

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

2 doses of placebo on Day 0 and Day 21

Placebo Group, high dose, 18-59 year-old

2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

2 doses of placebo on Day 0 and Day 21

Placebo Group, high dose, 60 year-old and above

2 doses of placebo (0µg, 0.5 ml) on Day 0 and Day 21

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

2 doses of placebo on Day 0 and Day 21

Interventions

COVID-19 mRNA vaccine

2 doses of vaccine on Day 0 and Day 21

Intervention Type: BIOLOGICAL

Placebo

2 doses of placebo on Day 0 and Day 21

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Adults aged 18 years and above with BMI of 18 to 30 (including boundary values);

2. Volunteers are able and willing to comply with the requirements of the clinical trial protocol, and volunteers or witnesses can sign informed consent forms;

3. Willing to discuss the medical history with the investigator or doctor and allow access to all medical records related to this trial;

4. Provide 48-hour PCR negative report;

5. Have not received any other COVID-19 vaccines.

4. Other reasons for exclusion that the investigators believe.

Exclusion Criteria

• Criteria for exclusion of the first dose

1. Other medical or psychiatric conditions, including recent (within the past year) or current presence of suicidal ideation/behavior, or laboratory abnormalities that may increase the risk of participating in the study, or subjects who are not suitable to participate in the study according to the investigator's judgment;

2. Positive for human immunodeficiency virus (HIV);

3. History of infection or disease of Middle East Respiratory Syndrome (MERS), SARS or other coronaviruses or related immunizations;

4. History of serious adverse reactions associated with the vaccine and/or a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine under study;

5. Immunocompromised patients with known or suspected immunodeficiency identified by medical history and/or physical examination;

6. Bleeding constitution or condition associated with prolonged bleeding which investigators believe that intramuscular injection is contraindicated;

7. Women who test positive for blood pregnancy or are breastfeeding, volunteers or their partners have a pregnancy plan within 12 months;

8. Severe hypertension and uncontrollable medication (on-site measurement: systolic blood pressure ≥ 160mmHg, diastolic blood pressure ≥ 100mmHg);

9. Have a serious chronic disease or the condition is in the progression period can not be smoothly controlled, such as diabetes, thyroid disease, etc.;

10. History of severe myocarditis, pericarditis and other heart diseases;

11. Abnormal laboratory tests during the screening window and judged by researchers to be of clinical significance;

12. Plans to receive other vaccines within 28 days before and after receiving the test vaccine;

13. Those receiving immunosuppressive therapy, including cytotoxic drugs or systemic corticosteroids, such as for cancer or autoimmune diseases, or who were scheduled to receive treatment throughout the study period. If systemic corticosteroids are used in a short period of time (< 14 days) for the treatment of acute illness, subjects should not enter this study until at least 28 days after corticosteroid therapy has been discontinued prior to study vaccination. Inhalation/spraying, intra-articular, intraskeletal, or topical (skin or eyes) use of corticosteroids is permitted;

14. Receiving blood/plasma products or immunoglobulins 60 days prior to study vaccination or plan to receive for the entire study duration;

15. Engage in other interventional studies within 28 days prior to entering the study and/or during the study's participation;

16. Participated in other interventional studies of lipid-containing nanoparticles;

17. Have symptoms of COVID-19 such as respiratory symptoms, fever, cough, shortness of breath, and dyspnea;

18. Fever, axillary temperature > 37.0 °C.

1. Severe allergic reactions occur after the first vaccination;

2. Serious adverse reactions with causal relationship during the first vaccination;

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

CanSino Biologics Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ruihua Dong

Role: PRINCIPAL_INVESTIGATOR

Beijing Friendship Hospital

Kexin Zhao

Role: PRINCIPAL_INVESTIGATOR

Hebei Petro China Center Hospital

Tao Huang

Role: PRINCIPAL_INVESTIGATOR

Hunan Provincial Center for Disease Control and Prevention

Locations

Beijing Friendship Hospital

Beijing, Beijing Municipality, China

Hebei Petro China Center Hospital

Langfang, Hebei, China

Hunan Provincial Center for Disease Control and Prevention

Changsha, Hunan, China

Countries

China

References

Jin Z, Wu J, Wang Y, Huang T, Zhao K, Liu J, Wang H, Zhu T, Gou J, Huang H, Wu X, Yin H, Song J, Li R, Zhang J, Li L, Chen J, Li X, Zhang M, Li J, Hou M, Song Y, Wang B, Gao Q, Wu L, Kong Y, Dong R. Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults. J Infect. 2023 Dec;87(6):556-570. doi: 10.1016/j.jinf.2023.10.012. Epub 2023 Oct 28.

Reference Type: DERIVED

PMID: 37898410 (View on PubMed)

Other Identifiers

CTP-NCVM-001

Identifier Type: -

Identifier Source: org_study_id